LGR5 and cancer: To study LGR5+ cells in vivo, we initially used an LGR5‐EGFP expressing organoid (clone #1) that by exome sequencing revealed few acquired mutations compared to the parental population, none of which affected known cancer driver genes (Appendix Table S3).